COVID-19 TREATMENT -CURRENT PROTOCOLS AND FUTURE PROSPECTS
DOI:
https://doi.org/10.47820/recima21.v2i4.251Keywords:
drug treatment, coronavirus, healthAbstract
Considering the relevance of covid-19 today, this study aimed to point out the main drugs that have become the target of study and clinical use in the treatment of the disease. The literature narrative review methodology on treatments previously tested for covid-19 was used, bringing together the most relevant and robust studies on each drug. Of the drugs evaluated, some had a positive influence on the healing time and reduction of symptoms caused by the disease. Among the drugs studied, remdesivir was the most prominent, reducing the time spent in the ICU and also the mortality rate. Heparin had a great positive influence linked to cases with a tendency to develop thrombosis. Dexamethasone demonstrated the power to reduce the chance of mortality and ivermectin acted in reducing the duration of the disease. Other drugs such as Azithromycin and Hydroxychloroquine have not been shown to be effective in studies of greater relevance and no data has been found to justify their use for the treatment of Covid-19. Despite the small amount of data to prove its effect against Covid-19, have shown positive potential and reduced the length of stay of patients in the hospital. To date, no specific medications have been approved to treat covid-19. The treatment of the disease focuses mainly on supportive care. However, Our bibliographic research has shown that some protocols demonstrate a positive outcome when compared to treatment without the use of any drugs.
Downloads
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2021 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.